Results 91 to 100 of about 29,074 (242)

Lineage switch of adult B-cell acute lymphoblastic leukaemia to acute myeloid leukaemia following B-cell-directed therapy

open access: yesEuropean Journal of Case Reports in Internal Medicine
Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL).
Oscar F. Borja-Montes   +6 more
doaj   +1 more source

Potent monoclonal antibodies against multidrug‐resistant hypervirulent Klebsiella pneumoniae

open access: yesInterdisciplinary Medicine, EarlyView.
A novel immunization strategy using a low‐virulence, multidrug‐resistant strain yields synergistic monoclonal antibodies against hypervirulent Klebsiella pneumoniae. These antibodies provide cross‐serotype protection through a dual‐mechanism of pathogen clearance and immunomodulation, offering a promising non‐antibiotic therapeutic for resistant ...
Yushan Jiang   +10 more
wiley   +1 more source

Immunotherapy‐Related Cutaneous Toxicities in Melanoma: A Dermoscopic Perspective

open access: yesJEADV Clinical Practice, EarlyView.
Dermoscopy serves as a valuable tool in the everyday dermatological and oncological practice for melanoma patients, allowing for the prompt identification of immune‐related cutaneous toxicities and guiding clinicians toward appropriate therapeutic decisions.
Grażyna Kamińska‐Winciorek   +3 more
wiley   +1 more source

bispecific antibody

open access: yes
Citation: 'bispecific antibody' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.12951 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms ...
openaire   +1 more source

Cutaneous Squamous Cell Carcinoma Amongst Solid Organ Transplant Recipients: A Systematic Review of Molecular Alterations

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background As solid organ transplantation becomes more prevalent, more patients are living on long‐term immunosuppression, greatly increasing the risk of cutaneous squamous cell carcinoma (cSCC). Although significant improvements have been achieved in the treatment of cSCC, further studies are needed to identify the specific protein expression
William Murray   +8 more
wiley   +1 more source

Hemophilia A: An Ideal Disease for Prenatal Therapy

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Hemophilia A (HA) is the most common inherited coagulation defect. Current state‐of‐the‐art treatment consists of frequent administration of prophylactic infusions of coagulation factor VIII (FVIII) protein or bispecific antibodies that replace the cofactor function of FVIIIa to maintain hemostasis. However, these treatments are far from ideal,
Christopher D. Porada   +2 more
wiley   +1 more source

Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies

open access: yesCell Reports Medicine
Summary: IMCnyeso, an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC) bispecific (New York esophageal squamous cell carcinoma [NY-ESO]×CD3) T cell engager, targets an NY-ESO-1/L-antigen family member-1 isoform A (LAGE-1A) peptide ...
Juanita S. Lopez   +12 more
doaj   +1 more source

A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

open access: yesPrecision Radiation Oncology, EarlyView.
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song   +5 more
wiley   +1 more source

Dendritic Cell‐T Cell Crosstalk Mediated Cancer Immunotherapy

open access: yes
Exploration, EarlyView.
Ying Cai, Jiameng Chen, Yaping Li
wiley   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy